



## PRELIMINARY SCORE

## CURATIVE



## NON-CURATIVE



## ADJUSTMENTS

## Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



## Serious and disabling adverse effects



## Other adjustments



## SCORE

## CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

## NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Zolbetuximab, a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive.

Experimental Arm: Zolbetuximab + Oxaliplatin + Leucovorin + Fluorouracil (mFOLFOX6)

Control Arm: Placebo + mFOLFOX6

